Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Apraglutide.

Research draft

Apraglutide is a long-acting GLP-2 analogue investigated for short bowel syndrome.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Apraglutide is a long-acting GLP-2 analogue investigated for short bowel syndrome.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It promotes intestinal adaptation and absorption-related responses.

Human research

Human short-bowel studies assess absorption and parenteral-support requirements; they do not establish a general gut-health benefit.

Preclinical & other research

Intestinal models support the adaptation rationale.

Safety & unknowns

Fluid balance, gastrointestinal effects and disease-specific monitoring matter.

Regulatory status

Clinical-development status and any authorisation require a dated jurisdiction-specific check.

Reported use & evidence

Research profile draft

The supplied Apraglutide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds